Moderna (MRNA.O) shares rose 20% in pre-market trading after the company and Merck announced that their melanoma skin cancer vaccine had met target impact in a large trial.
2026-08-19
Moderna (MRNA.O) shares rose 20% in pre-market trading after the company and Merck announced that their melanoma skin cancer vaccine had met target impact in a large trial.